Canaccord Genuity Group started coverage on shares of Niagen Bioscience (NASDAQ:NAGE - Free Report) in a research report sent to investors on Tuesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $13.00 price objective on the stock.
Niagen Bioscience Stock Performance
Shares of NASDAQ:NAGE traded up $0.38 during trading on Tuesday, reaching $10.98. 961,610 shares of the stock traded hands, compared to its average volume of 839,101. The company has a market capitalization of $864.89 million, a PE ratio of 64.59 and a beta of 1.94. The firm's 50-day moving average price is $8.00. Niagen Bioscience has a 52-week low of $2.31 and a 52-week high of $11.06.
Niagen Bioscience Company Profile
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Read More
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
